AA
LRMR icon

ALPS Advisors’s Larimar Therapeutics LRMR Stock Holding History

ALPS Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,460
Closed -$102K – 1044
2025
Q1 		$102K Sell
47,460
-4,130
-8% -$13.1K ﹤0.01% 979
2024
Q4 		$200K Buy
+51,590
New +$341K ﹤0.01% 972
2016
Q4 		– Sell
-2,903
Closed -$115K – 722
2016
Q3 		$115K Sell
2,903
-290
-9% -$13.2K ﹤0.01% 668
2016
Q2 		$229K Buy
3,193
+641
+25% +$50.7K ﹤0.01% 596
2016
Q1 		$205K Sell
2,552
-438
-15% -$34.6K ﹤0.01% 603
2015
Q4 		$226K Sell
2,990
-545
-15% -$87.5K ﹤0.01% 669
2015
Q3 		$1.36M Buy
3,535
+1,312
+59% +$592K 0.01% 196
2015
Q2 		$924K Buy
2,223
+1,139
+105% +$477K 0.01% 216
2015
Q1 		$515K Buy
+1,084
New +$515K ﹤0.01% 507

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ALPS Advisors's LRMR Position: Q2 2025 in Review

ALPS Advisors sold out of Larimar Therapeutics (LRMR) in Q2 2025, closing a stake of 47,460 shares — an estimated $102K sold.

ALPS Advisors first reported a position in LRMR in Q1 2015 and held it in 9 quarters. The position peaked at $1.36M in Q3 2015. 116 funds tracked by Wall St. Rank hold LRMR as of Q2 2025.

  • ALPS Advisors reported no remaining Larimar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ALPS Advisors sold 47,460 Larimar Therapeutics shares in Q2 2025, an estimated $102K.
  • ALPS Advisors first reported a position in Larimar Therapeutics in Q1 2015 and held it in 9 quarters.
  • ALPS Advisors's Larimar Therapeutics position peaked at $1.36M in Q3 2015.
  • 116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2025.

Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.